Pelosi Rx Pricing Bill Offers Big Savings, Big Drop In Drug Development – CBO
Overall effect on health of US families stemming from increased use of drugs but decreased availability of new drugs is 'unclear,' the Congressional Budget Office concludes in its preliminary analysis of HR 3.
You may also be interested in...
Not only does the CBO’s new model make the impact of draconian changes look small, it also gives a framework for compromise that could make legislation more likely to pass Congress.
A lot of new drugs aren’t really all that innovative, which complicates the view that lower profitability will mean less biopharma innovation.
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.